AUSTIN: Actinogen has received confirmation from an independent Dose Escalation Committee that its lead drug candidate, Xanamem, when dosed at 10mg, satisfies safety, tolerability and pharmacokinetic metrics.
This now allows for a dose escalation to 25mg for the next cohort of 8 participants.
Actinogen expects the next cohort to be dosed in late March. The clinical trial program continues to execute on time and on budget.
Xanamem is being developed as a new therapy for Alzheimer’s disease…